Results 161 to 170 of about 1,742,061 (410)

Genomic aberrations and survival in chronic lymphocytic leukemia.

open access: yesNew England Journal of Medicine, 2000
H. Döhner   +8 more
semanticscholar   +1 more source

MUTE‐Seq: An Ultrasensitive Method for Detecting Low‐Frequency Mutations in cfDNA With Engineered Advanced‐Fidelity FnCas9

open access: yesAdvanced Materials, EarlyView.
An advanced‐fidelity CRISPR nuclease, FnCas9‐AF2, is rationally engineered to discriminate single‐base mismatches with unprecedented level precision. Integrated into the MUTE‐Seq workflow, FnCas9‐AF2 depletes wild‐type cell‐free DNA, thereby exposing rare tumor‐derived mutant DNA (a molecular “needle in a haystack”).
Sunghyeok Ye   +20 more
wiley   +1 more source

P754: INITIAL RESULTS OF PHASE I/II STUDY OF AZACITIDINE IN COMBINATION WITH QUIZARTINIB FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME AND MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM WITH FLT3 OR CBL MUTATION

open access: yesHemaSphere, 2022
T. Abuasab   +9 more
doaj   +1 more source

Nanostructured Protein Surfaces Inspired by Spider Silk

open access: yesAdvanced Materials, EarlyView.
Harnessing recombinant spider silk technology, bioengineered spidroin variants enable the creation of functionalized nanostructured coatings with tunable affinity for specific targets, supporting a broad range of applications ‐ from antifouling surfaces and targeted drug delivery to advanced cell therapies and precision bio‐patterning via lithography ...
Martin Humenik, Thomas Scheibel
wiley   +1 more source

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

open access: yesNew England Journal of Medicine, 2006
B. Druker   +31 more
semanticscholar   +1 more source

Advances and Strategies in Enhancing mRNA Cancer Vaccines

open access: yesAdvanced Materials, EarlyView.
Messenger RNA (mRNA) vaccines offer a powerful approach for cancer immunotherapy, but their clinical impact remains limited by delivery challenges and suboptimal immune activation. This review discusses key biological barriers and design strategies—including structural optimization, immunomodulation, organ targeting delivery, and advanced nanocarriers ...
Miao Zhang   +4 more
wiley   +1 more source

P1066: OUTCOMES OF COVID-19 IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS - AN OBSERVATIONAL COHORT STUDY FROM A LARGE ACADEMIC CANCER CENTER IN THE UNITED STATES

open access: yesHemaSphere, 2022
S. Venugopal   +13 more
doaj   +1 more source

Home - About - Disclaimer - Privacy